PER-057-03未知未知
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY, INDUCED UNDER INTERNAL BLIND CONDITIONS, TO DETERMINE THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF THE APREPITANT REGIME COMPARED TO AN ONDASETRON REGIME FOR THE PREVENTION OF NAUSEA AND VOMITES INDUCED BY CHEMOTHERAPY, ASSOCIATED WITH HIGH DOSE OF CISPLATINO IN CYCLE 1.
MERCK & CO.INC.,0 个研究点目标入组 0 人开始时间: 2003年10月28日最近更新:
试验速览
- 阶段
- 未知
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •The patient is> 18 years of age.
- •The patient is scheduled to receive his first cycle of cisplatin chemotherapy for a malignant solid tumor documented at a dose of> 70 mg / m administered for <3 hours.
- •The patient has Kamofsky score> 60.
- •The patient has a predicted life expectancy of> 3 months.
排除标准
- •The patient is mentally incapacitated or has a significant emotional or psychiatric disorder that, in the opinion of the investigator, excludes him from participating in the study.
- •The patient receives stem cell rescue therapy along with the cisplatin chemotherapy cycle.
- •The patient has received an unapproved (investigational) drug within the last 4 weeks.
研究者
相似试验
已完成
不适用
A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY ASSESSING THE EFFICACY AND SAFETY OF SARILUMAB MONOTHERAPY VERSUS ADALIMUMAB MONOTHERAPY IN PATIENTS WITH RHEUMATOID.PER-081-14Sanofi Aventis Recherche & Development,18
未知
不适用
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF 52 WEEKS OF ONCE DAILY TREATMENT OF ORALLY INHALED TIOTROPIUM + OLODATEROL FIXED DOSE COMBINATION (2.5 µG / 5 µG; 5 µG / 5 µG) (DELIVERED BY THE RESPIMAT) COMPARED…PER-089-11Boehringer Ingelheim,
进行中（未招募）
1 期
A study to evaluate the safety and efficacy of switching from regular infliximab to biosimilar infliximab in patients with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease and psoriasisEUCTR2014-002056-40-NODiakonhjemmet Hospital AS498
未知
不适用
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY OF THE SAFETY AND THE EFFECT ON CLINICAL OUTCOME OF TOCILIZUMAB SC VERSUS PLACEBO SC IN COMBINATION WITH TRADITIONAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS) IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITISPER-028-11F. HOFFMANN-LA ROCHE LTD.,
进行中（未招募）
不适用
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF CO ADMINISTRATION OF TRIPLE COMBINATIONS OF OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE, AND HYDROCHLOROTHIAZIDE COMPARED WITH THE CORRESPONDING OLMESARTAN- AMLODIPINE COMBINATION IN SUBJECTS WITH HYPERTENSIOEUCTR2008-003534-25-DEDAIICHI SANKYO EUROPE GmbH2,689